NCI-60 Cell Line Screening: A Radical Departure in its Time.
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 26755050.
- Also identified by DOI 10.1093/jnci/djv388.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
The year 2015 marked the 30th anniversary of National Cancer Institute's (NCI's) initial effort to establish a human cell line panel as the basis for discovering new cancer drugs. At its inception, the NCI-60 panel was a controversial departure, born of frustration with previous efforts that employed murine tumors and grounded in the hope that the biology of human tumors was diverse and somehow quite different than the murine leukemia used for the previous 30 years. And while the NCI-60 has not revolutionized cancer drug discovery in terms of the new drugs that resulted, it represents a turning point in the philosophy and practice of cancer drug research.
Medical subject headings
- Antineoplastic Agents
- Cell Line, Tumor
- Drug Discovery
- Molecular Targeted Therapy
- National Cancer Institute (U.S.)